# Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

> **NCT02597803** · PHASE2,PHASE3 · COMPLETED · sponsor: **ReGenTree, LLC** · enrollment: 317 (actual)

## Conditions studied

- Dry Eye Syndrome

## Interventions

- **DRUG:** RGN-259
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02597803
- **Lead sponsor:** ReGenTree, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-06
- **Final completion:** 2016-07
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2019-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597803, "Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02597803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*